Trevena Q4 net loss $16.5M; reduces OLINVYK support, reviews alternatives

TREVENA INC

2024-Q1 EPS reported -$0.36

Net loss $16.5M ($1.06/share) vs $7.0M ($0.73/share) in Q4 2022.
FY2023 net loss $40.3M ($3.16/share); cash $33.0M as of Dec 31, 2023.
Reducing OLINVYK commercial support; reviewing strategic alternatives including sale or license.
TRV045 advances toward Phase 2 readiness with positive PoC data in neuropathic pain and epilepsy.
TRV045 showed no lymphopenia, bradycardia, or BP changes vs other S1P modulators.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TREVENA INC reported fourth quarter ended December 31, 2023 results: net income $16.5 million, EPS $1.06 per share.

Period: fourth quarter ended December 31, 2023
Net income: $16.5 million
EPS: $1.06 per share
Result: reported results

Exact text from the filing

For the fourth quarter of 2023, the Company reported a net loss attributable to common stockholders of $16.5 million, or $1.06 per share, compared to $7.0 million, or $0.73 per share in the fourth quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TREVENA INC reported full year ended December 31, 2023 results: net income $40.3 million, EPS $3.16 per share.

Period: full year ended December 31, 2023
Net income: $40.3 million
EPS: $3.16 per share
Result: reported results

Exact text from the filing

For the full year ended December 31, 2023, net loss attributable to common stockholders was $40.3 million, or $3.16 per share, compared to $53.7 million, or $7.59 per share.

View on SEC.gov

324 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-041321

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.